Glucose Monitoring Global Market

–Forecast to 2027

Glucose Monitoring global Market estimated to be worth $15,321.8 million by

2027

IQ4I Research & Consultancy published a new report on “Glucose Monitoring Global
Market – Forecast To 2027” This report analyzes and studies the overall market, major
Drivers & Opportunities, Restraints & Threats in North America, Europe, Asia-Pacific and
Rest of the World.

IQ4I’s Report Contains 93 market data tables and 129 figures spread through 398
pages and an exhaustive TOC on “Glucose Monitoring Global Market[PRODUCTS
{Invasive Glucose Monitoring [Self Blood Glucose Monitoring (Blood Glucose Meter,
Blood Glucose Testing Strips, Lancets and Others)], Continuous Glucose Monitoring
(Glucose Sensors and Transmitter & Receiver)], Non-Invasive and Lab Based Glucose
Monitoring}, SAMPLE SOURCE [Blood based, Urine based and others], END-USER
(Hospitals, Private Clinics, Home Care and Ambulatory Settings), REGION (North
America, Europe, Asia-Pacific and Rest of the World)].

Diabetes is a chronic disease condition in which the blood glucose level regulation is varied
because the body lacks enough insulin (a hormone that controls the level of sugar in the
blood) or the body cannot utilize the insulin that is produced. Three types of diabetic
conditions have been identified, type 1 diabetes, wherein the body does not produce insulin,
type 2 diabetes, which is the most common type, the body does not make or use insulin well
and gestational diabetes which affects pregnant women. Having too much glucose in the
blood can cause serious problems to vital organs including the eyes, kidneys, and nerves.
Long term complication of diabetes includes cardiovascular diseases, (coronary artery
disease, heart attack, stroke, and atherosclerosis), neuropathy (nerve damage),
nephropathy (kidney damage), retinopathy (eye damage), and other conditions.

Monitoring the blood sugar level regularly and analyzing the results is crucial in managing
diabetes. Self-monitoring of blood glucose level is an integral part of diabetes management
because it puts the patient in charge. Regardless of managing diabetes through diet and
exercise alone or combined with oral medicines or insulin, regular blood sugar monitoring
provides immediate feedback on how the program is working. Glucose meters are used to
self-monitor the blood glucose levels at home or clinics. At hospitals, lab analysis such as
Hb1Ac, urine tests are used to monitor the levels of glucose, which are often time-
consuming. According to IQ4I Research, the glucose monitoring global market is expected to
grow at low single digit CAGR from 2020 to 2027 to reach $15,321.8 million by 2027.

The global rise in the prevalence and incidence of diabetes, increasing demand for less
minimally invasive or non-invasive and point-of-care devices, increasing R&D investments

IQ4I Research & Consultancy Pvt. Ltd. Page 1

Glucose Monitoring Global Market

–Forecast to 2027

are driving the market growth, whereas, the growing diffusion of smart devices and digital
platforms increasing compliance and management of diabetes is creating opportunities in
the coming years. The high cost of the products, frequent product recalls and inadequate
reimbursement is restraining the market growth. The stringent regulations, privacy concerns
and safety issues are threats for the market growth.

Glucose Monitoring global market is classified based on products, sample type, end-users
and geography. Among the product segments, The Invasive glucose monitoring products
segment accounted for the largest share in 2020 and is projected to grow at low single digit
CAGR from 2020 to 2027 due to technological advancements, easy use, and reliability, etc.
The invasive glucose monitoring products are further sub-segmented into self-glucose
monitoring devices and continuous glucose monitoring devices, among self-glucose
monitoring devices, blood glucose testing strips commanded the largest share of the market
in 2020, similarly, among the continuous glucose monitoring devices, sensors commanded
the largest share of the revenue in 2020.The non-Invasive glucose monitoring segment is
the fastest-growing segment and is projected to grow at a high single digit CAGR from 2020
to 2027 due to an increase in R&D investments, and regulatory approvals.

Among the sample type, the blood segment accounted for the largest share in 2020 and is
projected to grow at low single digit CAGR from 2020 to 2027 due to the accuracy of results.
Other source-based glucose monitoring segment is the fastest-growing segment and is
projected to grow at strong double digit CAGR from 2020 to 2027 due to an increase in R&D
investment, increasing demand from users for non-invasive products.

Among end-user segments, the home care segment accounted for the largest share in 2020
and is projected to grow at low single digit CAGR from 2020 to 2027 due to the availability of
self blood monitors over-the-counter and ease in operating these monitors and thereby
reducing the frequent visit to hospitals or clinics for checking glucose levels.

In the market segmentation based on geography, North America commanded the largest
market share in 2020 due to the rapid adoption of advanced technology, favorable
reimbursement coverage and high investments in healthcare infrastructures that have led to
the market growth in this region. However, Asia- Pacific region is expected to grow at mid
single digit CAGR from 2020 to 2027 due to increasing healthcare awareness, higher
economic growth, a large patient pool and rising aged population.

IQ4I Research & Consultancy Pvt. Ltd. Page 2

Glucose Monitoring Global Market

–Forecast to 2027

Various advancements in glucose detecting technologies such as wireless smart contact

lenses, saliva-based biosensors and the radiofrequency sensor for CGM are under different
stages of development and launch. For instance, Scientists from the Department of Materials
Sciences and Engineering, Pohang University of Science and Technology (POSTECH),
South Korea have developed a remotely controllable smart contact lens for non-invasive
glucose monitoring and controlled drug delivery. The lens consists of five parts: a real-time
electrochemical biosensor, an on-demand flexible drug delivery system (f-DDS), a resonant
inductive wireless energy transfer system, a complementary integrated circuit (IC)–based
microcontroller chip with a power management unit (PMU), and a remote radio frequency
(RF) communication system. The biosensor in the lens detects glucose in the tears by the
real-time amperometric method. The resonant inductive coupling to a copper (Cu) receiver
coil allows wireless powering from an external power source with a transmitter coil. The
device communicates with an external controller by RF communication.

According to IQ4I analysis, globally there were about 472.2 million people affected with
diabetes in 2020, this consists of XX million Type 1 diabetes and XX million type 2 diabetes
patients. However, only XX% of this population is diagnosed and are recommended to use
some form of glucose monitoring device to avoid complications arising of diabetes, but due
to various reason, the diabetic population fail to comply with monitoring regimen constituting
about to XXmillion people. About XX% of the diagnosed population or XX million people
around the world use either (XX million) continuous glucose monitoring or (XX million) self
glucose monitoring device. The number of sensors used by CGM users is estimated to be
XX million in 2020 and is estimated to XX million by 2027 growing at double digit CAGR from
2020 to 2027. Similarly, about XX million glucose monitoring strips were used by people
using self glucose monitoring devices.

Considering the huge unmet opportunity in this market many investors are funding the
development of new glucose monitoring technologies, According to IQ4I analysis, close to
$XX million funding was provided starting January 2020. For instance, in March 2021,
Glooko received $30.0 million in funding from Health Catalyst Capital, Canaan Partners,
Georgian, Novo Nordisk, Insulet, and Mayo Clinic to accelerate the company's remote
patient monitoring platform's adoption, widening commercialization of products in clinical
research and expanding into additional therapy areas. Similarly, in June 2020, Medtronic
received $337.0 million in funding from Blackstone Life Sciences to accelerate Medtronic's
four programs in insulin pump and continuous glucose monitoring pipeline.

IQ4I Research & Consultancy Pvt. Ltd. Page 3

Glucose Monitoring Global Market

–Forecast to 2027

The glucose monitoring market is consolidated and is dominated by players such as Abbott
Dexcom, Roche, LifeScan, Ascensia, Medtronic, Sinocare, and B.Braun controlling around
XX% of the market, as these companies have a strong distribution network and have
multiple channels to reach the patients, whereas, in CGM market is set to see several new
companies entering the market with innovative products, for instance, Medtrum, a Chinese
company has developed Touchcare CGM, A6 and A7+ systems which have received CE
mark approval, similarly, Waveform Technologies, Inc., (Agamatrix) has developed CGM
system and has been launched in select European countries in 2020 in partnership with
Menarini under the brand name Glucomen.

To popularize the adoption and to fully exploit the potential of CGM systems, Time in Range
(TIR) has been adopted as a new metric, which has been endorsed by American Diabetes
Association (ADA), Time In Range metric explains the duration of time patients with diabetes
spent within the prescribed range of 70-180mg/dL in a day to prevent any complications.

As CGM technology matures, it is finding non-diabetic use such as personal-use product for
lifestyle management and as a tool to improve athlete’s performance, for instance, Abbott in
September 2020, received CE approval for its world’s first sports-centric CGM, the Libre
Sense Glucose Sport biosensor which is designed to continuously measure glucose levels
and their performance. The Libre Sense Glucose Sport Biosensor is a consumer over-the-
counter product designed for performing sports such as cycling, running, and swimming, to
understand the efficacy of their nutrition choices on training and competition. To promote this
product Abbott has tied up with Supersapiens, an Atlanta-based sports technology company
that is focusing on providing athletes with actionable and personalized insights on real-time
biometric data, starting with glucose. The product is currently available in eight European
countries namely Austria, France, Germany, Ireland, Italy, Luxembourg, Switzerland, and the
United Kingdom.

New companies are starting to exploit CGM technology as a lifestyle tool, for instance, the
U.S.-based Levels Health is promoting the use of CGMs to make it easy for people to
understand how their diet and lifestyle affect their health through their Levels app. They help
the subscribed members to find their optimal diet and improve the metabolic health. To
augment their efforts, In November 2020, Levels Health received $12.0 million in
investments from A16Z for the development of biowearable to provide real-time feedback on
how diet impacts health.

IQ4I Research & Consultancy Pvt. Ltd. Page 4

Glucose Monitoring Global Market

–Forecast to 2027

Major players in the glucose monitoring market include Abbott Laboratories (U.S.), Dexcom
(U.S.), Roche (Switzerland), LifeScan (U.S.), Medtronic, Inc. (Ireland), PHC Holding
(Ascensia) (Japan), B. Braun Melsungen AG (Germany), Sinocare (China), i-Sens, Inc.,
(South Korea), and Arkray (Japan), etc.

Reasons for buying this report:

 Identification and analysis of the Glucose Monitoring market by identifying various
segments by products, sample type, end-users and geography.
 Market share analysis for overall glucose monitoring global market, self glucose
monitoring, continuous glucose monitoring and regional SMBG and CGM market.
 Revenue forecast of Glucose Monitoring global market and strategic analysis of each
sub-segment with respect to segmental growth trends.
 Identification of major market trends, Porter's model and factors driving and
restraining Glucose Monitoring products market growth.
 Revenue forecast of the Glucose Monitoring market with respect to North America
(U.S. and Rest of N.A.), Europe (Germany, France, Italy and Rest of E.U.), Asia-
Pacific (Japan, China, India and Rest of APAC) and Rest of the World (RoW) (Brazil,
Rest of Latin America and Middle-East & Others) regions.
 Analysis of the opportunities for stakeholders by identifying the high-growth
segments of the market.
 Analyzing funding and patent filing trend to assess innovation activities.
 Identification of key technology developments and innovations driving the market.
 Profiles of major players in the Glucose Monitoring market and analysis of their
product offerings, financial revenue, business strategies, SWOTs and market shares.
 Price analysis of glucose monitoring monitors, strips, sensors and transmitters,
market penetration calculation regional and country wise.

IQ4I Research & Consultancy Pvt. Ltd. Page 5

Glucose Monitoring Global Market

–Forecast to 2027

FIGURE 1

GLUCOSE MONITORING GLOBAL MARKET SEGMENTATION

Glucose Monitoring Global Market

By Products By Sample By End-Users

Invasive Non invasive Lab based

Blood Hospitals
Products Products Products

Urine Home Care

Self-Monitoring Continuous Glucose
Glucose Monitoring Monitoring
Others Private clinics
Blood Meter Sensors
Glucose Ambulatory
Blood Glucose Transmitter and settings
Testing Strips Receivers

Lancets

Others

IQ4I Research & Consultancy Pvt. Ltd. Page 6